Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia

Stacie B. Dusetzina, Benjamin L. Cook, Alisa B. Busch, G. Caleb Alexander, Haiden A. Huskamp

Research output: Contribution to journalArticle

Abstract

Objective: Prior investigations suggest that olanzapine use declined rapidly after a U.S. Food and Drug Administration (FDA) communication and consensus statement warning of the drug's increased metabolic risks, but whether declines differed by racial-ethnic groups is unknown. Methods: Changes in olanzapine use over time by raceethnicity was assessed among 7,901 Florida Medicaid enrollees with schizophrenia. Results: Prior to the advisory, 57% of secondgeneration antipsychotic fills among Hispanics were for olanzapine, compared with 40% for whites or blacks (adjusted risk difference [ARD]=.17, 95% confidence interval [CI]=.13-.20). Olanzapine use declined among all racial-ethnic groups. Although Hispanics had greater olanzapine use than whites in each period, the differences in absolute risk were only 3% by the latest study period (ARD=.03, CI=.01-.04). Conclusions: After the FDA communication and consensus statement were issued, differences in olanzapine use between white and Hispanic enrollees narrowed considerably. Identifying high-use subgroups for targeted delivery of drug safety information may help eliminate any existing differences in prescribing.

Original languageEnglish (US)
Pages (from-to)83-87
Number of pages5
JournalPsychiatric Services
Volume64
Issue number1
DOIs
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia'. Together they form a unique fingerprint.

  • Cite this